What is the main business of Przedsiębiorstwo Farmaceutyczno-Chemiczne Synteza?

The main business activity of Przedsiębiorstwo Farmaceutyczno-Chemiczne Synteza focuses on manufacture of pharmaceutical preparations.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on July 30, 2002.

Where is the headquarters located?

The headquarters is located at: Św. Michała 67/71, 61-005 Poznań.

What is the share capital?

The share capital of the company is PLN 9,435,000 (approx. $2.5 million).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.

What was the revenue?

In 2024, the company generated total revenue of $7,742,735, representing an increase of 16.3% compared to 2023.

Yes, the company recorded a net profit of $778,485 in 2024, meaning the company increased its profit by 105.7%.

What is the largest operating cost?

The largest operating cost category falls under employee remuneration. This category amounted to $2,559,204 in 2024, representing 38% of all operating expenses.

Przedsiębiorstwo Farmaceutyczno-Chemiczne Syntezasp. z o.o.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2002-07-30

Share capital

9,435,000.00 PLN

Registered address

św. Michała 67/71, 61-005 Poznań, Poland

Electronic delivery address

AE:PL-49124-31872-DHJJF-25

Financials

Revenue history (in k)

Filing timeliness

No financial statement for 2025 – the filing deadline has passed. 6 of 6 financial statements were filed late (the longest delay 453 days for 2023). All were audited by a statutory auditor.

2025not filed
202411/10/2025
202311/10/2025
202205/02/2024
202102/09/2022
202002/12/2021

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2024.

Results vs industry

Revenue

This companyUSD 7.74mMedianUSD 917.74kAverageUSD 25.73m

Net profit

This companyUSD 778.49kMedianUSD 14.44kAverageUSD 2.75m

Operating costs

This companyUSD 6.77mMedianUSD 860.03kAverageUSD 21.34m

Assets

This companyUSD 10.09mMedianUSD 883.09kAverageUSD 31.39m

Industry

Trademarks

Przedsiębiorstwo Farmaceutyczno-Chemiczne Synteza holds 41 active trademarks registered with the Polish Patent Office. 1 application is pending. 10 marks have expired or were not registered. The first mark was filed in 1969.

Mark	Number	Classes	Status	Protected until
PHARM SYNTEZA COSMETICS	Z.518844	3	Protected	Sep 25, 2030
TRAMADOL SYNTEZA S	Z.513873	5	Protected	May 25, 2030
DEZASEPT	Z.512732	5	Protected	Apr 21, 2030
DEZASEPT(word)	Z.511529	5	Protected	Mar 16, 2030
ANDEPIN(word)	Z.479446	5	Protected	Nov 27, 2027

Mark	Protected until
PHARM SYNTEZA COSMETICS	Sep 25, 2030
TRAMADOL SYNTEZA S	May 25, 2030
DEZASEPT	Apr 21, 2030
DEZASEPT(word)	Mar 16, 2030
ANDEPIN(word)	Nov 27, 2027

Authorized Representatives

Bernard Jan Wilkosz – Attorney-in-fact (sole)

Michał Szaban – President of the Management Board

Michał Woźny – Management Board Member

Manner of representation

President of the Management Board – independently, two members of the management board – jointly, a member of the management board and a commercial proxy – jointly.

Supervisory board

Alicja Maria Zalejska – Supervisory Board Member

Andrzej Mroczkiewicz – Supervisory Board Member

Edward Rinaldo Mataczyński – Supervisory Board Member

Jan Krzyżaniak – Supervisory Board Member

Stanisław Pańczak – Supervisory Board Member

Beneficial owners

Person	Rights

Subsidiaries

	Name	Share value	Stake
	Operator Lechickasp. z o.o.	464,073.47 USD	99.8837%

Bank accounts

Registered as a VAT taxpayer on 1995-07-03.

PKO Bank Polski
83 1020 4027 0000 1802 0032 8344
PKO Bank Polski
37 1020 4027 0000 1102 0046 8710
Erste Bank Polska
48 1500 1054 1210 5000 5985 0000

Debt

No entries in the National Debtors Register (KRZ).

Public aid

117 public aid cases recorded, with a total value of $2,678,414.

Grant date	Purpose	Gross amount	Granting body
Jul 28, 2026	Aid in the form of wage subsidies for employing workers with disabilities	$2,886$2,886	Prezes Zarządu Państwowego Funduszu Rehabilitacji Osób Niepełnosprawnych
Jun 30, 2026	Aid in the form of wage subsidies for employing workers with disabilities	$2,886$2,886	Prezes Zarządu Państwowego Funduszu Rehabilitacji Osób Niepełnosprawnych
May 26, 2026	Aid in the form of wage subsidies for employing workers with disabilities	$2,886$2,886	Prezes Zarządu Państwowego Funduszu Rehabilitacji Osób Niepełnosprawnych

European Funds

Start	Project	EU co-financing	Programme
2019-07-01	Conducting research and development to develop a technology for manufacturing a two-component medicine for pain therapy	$423.3K$423,320	Wielkopolska Regional Operational Programme for 2014 – 2020
2018-01-01	Establishment of the „Synteza” Research and Development Centre	$804.2K$804,243	Operational Programme Smart Growth

Regulatory authorisations

Authority	Type	Status
BDO	BDO register entry	Active

Competitors

Name	Revenue	Website
Delpharm PoznańS.A.	$110,900,246.81	delpharm.com
Phytopharm KlękaS.A.	$46,154,888.31	phytopharm.pl
Poznańskie Zakłady Zielarskie HerbapolS.A.	$31,668,225.77	herbapol.poznan.pl
Curtis Health CapsS.A.	$30,831,117.38	chc.com.pl
Przedsiębiorstwo Farmaceutyczne Farmapolsp. z o.o.	$21,462,728.43	farmapol.pl
Przedsiębiorstwo Produkcyjno-Handlowe EwaS.A.	$14,322,437.53	ewa-sa.pl
MedicofarmaS.A.	$8,530,473.72	medicofarma.pl
Krakowskie Zakłady Zielarskie Herbapol w KrakowieS.A.	$7,294,338.51	herbapol.krakow.pl
Labofarmsp. z o.o.	$6,814,569.78	labofarm.pl
VitamaS.A.	$4,287,087.38	vitama.pl